175 related articles for article (PubMed ID: 1531951)
41. 2-Hydroxylation of ethinyloestradiol in relation to the oxidation of sparteine and antipyrine.
Back DJ; Maggs JL; Purba HS; Newby S; Park BK
Br J Clin Pharmacol; 1984 Oct; 18(4):603-7. PubMed ID: 6487500
[TBL] [Abstract][Full Text] [Related]
42. CYP2D6 and ABCB1 genetic variability: influence on paroxetine plasma level and therapeutic response.
Gex-Fabry M; Eap CB; Oneda B; Gervasoni N; Aubry JM; Bondolfi G; Bertschy G
Ther Drug Monit; 2008 Aug; 30(4):474-82. PubMed ID: 18641553
[TBL] [Abstract][Full Text] [Related]
43. The effect of paroxetine on the pharmacokinetics, safety, and tolerability of ramosetron in healthy subjects.
Kadokura T; den Adel M; Krauwinkel WJ; Takeshige T; Nishida A
Eur J Clin Pharmacol; 2008 Jun; 64(6):605-9. PubMed ID: 18401578
[TBL] [Abstract][Full Text] [Related]
44. Imipramine demethylation and hydroxylation: impact of the sparteine oxidation phenotype.
Brøsen K; Otton SV; Gram LF
Clin Pharmacol Ther; 1986 Nov; 40(5):543-9. PubMed ID: 3769385
[TBL] [Abstract][Full Text] [Related]
45. Ultrarapid metabolism of sparteine: frequency of alleles with duplicated CYP2D6 genes in a Danish population as determined by restriction fragment length polymorphism and long polymerase chain reaction.
Bathum L; Johansson I; Ingelman-Sundberg M; Hørder M; Brøsen K
Pharmacogenetics; 1998 Apr; 8(2):119-23. PubMed ID: 10022749
[TBL] [Abstract][Full Text] [Related]
46. Metabolism of almitrine in extensive and poor metabolisers of debrisoquine/sparteine.
Herchuelz A; Gangji D; Derenne F; Jeanniot JP; Douchamps J
Br J Clin Pharmacol; 1991 Jan; 31(1):73-6. PubMed ID: 2015173
[TBL] [Abstract][Full Text] [Related]
47. Sparteine and mephenytoin oxidation: genetic polymorphisms in east and west Greenland.
Clasen K; Madsen L; Brøsen K; Albøge K; Misfeldt S; Gram LF
Clin Pharmacol Ther; 1991 Jun; 49(6):624-31. PubMed ID: 2060251
[TBL] [Abstract][Full Text] [Related]
48. [Phenotypes of oxidation and acetylation in Alzheimer's disease--preliminary report].
Milejski P; Orzechowska-Juzwenko K; Niewiński P; Hurkacz M; Czarnik-Matusewicz H; Leszek J; Rudzik J; Grotthus B
Psychiatr Pol; 2007; 41(2):261-9. PubMed ID: 17598435
[TBL] [Abstract][Full Text] [Related]
49. The selective serotonin reuptake inhibitor paroxetine is effective in the treatment of diabetic neuropathy symptoms.
Sindrup SH; Gram LF; Brøsen K; Eshøj O; Mogensen EF
Pain; 1990 Aug; 42(2):135-144. PubMed ID: 2147235
[TBL] [Abstract][Full Text] [Related]
50. A dose-effect study of the in vivo inhibitory effect of quinidine on sparteine oxidation in man.
Nielsen MD; Brøsen K; Gram LF
Br J Clin Pharmacol; 1990 Mar; 29(3):299-304. PubMed ID: 2310654
[TBL] [Abstract][Full Text] [Related]
51. Inter-ethnic difference in sparteine oxidation among Ghanaians and Germans.
Eichelbaum M; Woolhouse NM
Eur J Clin Pharmacol; 1985; 28(1):79-83. PubMed ID: 3987789
[TBL] [Abstract][Full Text] [Related]
52. Effect of CYP2D6 metabolizer status on the disposition of the (+) and (-) enantiomers of perhexiline in patients with myocardial ischaemia.
Inglis SC; Herbert MK; Davies BJ; Coller JK; James HM; Horowitz JD; Morris RG; Milne RW; Somogyi AA; Sallustio BC
Pharmacogenet Genomics; 2007 May; 17(5):305-12. PubMed ID: 17429312
[TBL] [Abstract][Full Text] [Related]
53. The influence of enzyme induction on polymorphic sparteine oxidation.
Eichelbaum M; Mineshita S; Ohnhaus EE; Zekorn C
Br J Clin Pharmacol; 1986 Jul; 22(1):49-53. PubMed ID: 3741726
[TBL] [Abstract][Full Text] [Related]
54. Influence of enzyme induction and inhibition on the oxidation of nifedipine, sparteine, mephenytoin and antipyrine in humans as assessed by a "cocktail" study design.
Schellens JH; van der Wart JH; Brugman M; Breimer DD
J Pharmacol Exp Ther; 1989 May; 249(2):638-45. PubMed ID: 2724144
[TBL] [Abstract][Full Text] [Related]
55. [The importance of examining genetic polymorphism of drug oxidation in psychiatry].
Beszłej JA; Kiejna A
Psychiatr Pol; 1995; 29(1):45-56. PubMed ID: 7878153
[TBL] [Abstract][Full Text] [Related]
56. [Clinical significance of oxidation and acetylation genetic polymorphism in patients with Parkinson's disease].
Milejski P; Orzechowska-Juzwenko K; Kamienowski J; Horoch E; Niewiński P; Hurkacz M; Rzemisławska Z
Neurol Neurochir Pol; 1999; 33(5):1015-24. PubMed ID: 10672554
[TBL] [Abstract][Full Text] [Related]
57. [Clinical significance of the determination of oxidation and acetylation phenotype in patients with multiple sclerosis].
Milejski P; Orzechowska-Juzwenko K; Pawlik J; Kamienowski J; Horoch E; Niewiński P; Hurkacz M
Neurol Neurochir Pol; 1996; 30(4):571-9. PubMed ID: 9045059
[TBL] [Abstract][Full Text] [Related]
58. The oxidative metabolism of sparteine in the Cuna Amerindians of Panama: absence of evidence for deficient metabolizers.
Arias TD; Jorge LF; Lee D; Barrantes R; Inaba T
Clin Pharmacol Ther; 1988 Apr; 43(4):456-65. PubMed ID: 3356089
[TBL] [Abstract][Full Text] [Related]
59. Influence of CYP2D6 genotype and medication on the sparteine metabolic ratio of psychiatric patients.
Lohmann PL; Rao ML; Ludwig M; Griese EU; Zanger UM; Mörike K; Maier W; Bagli M
Eur J Clin Pharmacol; 2001 Jul; 57(4):289-95. PubMed ID: 11549206
[TBL] [Abstract][Full Text] [Related]
60. Pharmacokinetics of dextromethorphan after single or multiple dosing in combination with quinidine in extensive and poor metabolizers.
Pope LE; Khalil MH; Berg JE; Stiles M; Yakatan GJ; Sellers EM
J Clin Pharmacol; 2004 Oct; 44(10):1132-42. PubMed ID: 15342614
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
